Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; the references it cites are not checked yet.

Liraglutide Improves Pancreatic Beta Cell Mass and Function in Alloxan-Induced Diabetic Mice

Open access

Abstract

Glucagon-like peptide-1 (GLP-1) receptor agonists potentiate glucose-induced insulin secretion. In addition, they have been reported to increase pancreatic beta cell mass in diabetic rodents. However, the precise mode of action of GLP-1 receptor agonists still needs to be elucidated. Here we clarify the effects of the human GLP-1 analog liraglutide on beta cell fate and function by using an inducible Cre/loxP-based pancreatic beta cell tracing system and alloxan-induced diabetic mice. Liraglutide was subcutaneously administered once daily for 30 days. The changes in beta cell mass were examined as well as glucose tolerance and insulin secretion. We found that chronic liraglutide treatment improved glucose tolerance and insulin response to oral glucose load. Thirty-day treatment with liraglutide resulted in a 2-fold higher mass of pancreatic beta cells than that in vehicle group. Liraglutide increased proliferation rate of pancreatic beta cells and prevented beta cells from apoptotic cells death. However, the relative abundance of YFP-labeled beta cells to total beta cells was no different before and after liraglutide treatment, suggesting no or little contribution of neogenesis to the increase in beta cell mass. Liraglutide reduced oxidative stress in pancreatic islet cells of alloxan-induced diabetic mice. Furthermore, the beneficial effects of liraglutide in these mice were maintained two weeks after drug withdrawal. In conclusion, chronic liraglutide treatment improves hyperglycemia by ameliorating beta cell mass and function in alloxan-induced diabetic mice.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pone.0126003

Cites

Statistics

Figures

Fig 1 Metabolic parameters in alloxan-diabetic mice treated with vehicle or liraglutide for 30 days. (a) Schematic representation of the study. (b) Body weight. There is no difference between two groups. (c) Food intake. Liraglutide slightly decreased food intake compared with vehicle. (d) Blood glucose. Blood glucose levels were significantly lower in liraglutide-treated group than in vehicle-treated group after day 13. (e) Serum insulin. Serum insulin levels were significantly higher in liraglutide-treated group than in vehicle-treated group on day 30. White circles and bars represent vehicle-treated group (Veh) (n = 9–13), and black circles and bars represent liraglutide-treated group (Lir) (n = 10–15). *p < 0.05, **p < 0.01
Fig 1 Metabolic parameters in alloxan-diabetic mice treated with vehicle or liraglutide for 30 days. (a) Schematic representation of the study. (b) Body weight. There is no difference between two groups. (c) Food intake. Liraglutide slightly decreased food intake compared with vehicle. (d) Blood glucose. Blood glucose levels were significantly lower in liraglutide-treated group than in vehicle-treated group after day 13. (e) Serum insulin. Serum insulin levels were significantly higher in liraglutide-treated group than in vehicle-treated group on day 30. White circles and bars represent vehicle-treated group (Veh) (n = 9–13), and black circles and bars represent liraglutide-treated group (Lir) (n = 10–15). *p < 0.05, **p < 0.01CC BY · PubMed Central
Fig 2 Oral glucose tolerance test (OGTT). Blood glucose and serum insulin levels during 1.5 g/kg OGTT on day 15 (a) and day 30 (b) are shown. Glucose tolerance was significantly improved by liraglutide treatment. Although insulin response was not detected in vehicle treated group, liraglutide improved the response. Insulinogenic index was significantly higher in liraglutide-group than vehicle-group on day 30. White circles and bars represent vehicle-treated group (Veh) (n = 5–6), and black circles and bars represent liraglutide-treated group (Lir) (n = 5–6). *p < 0.05
Fig 2 Oral glucose tolerance test (OGTT). Blood glucose and serum insulin levels during 1.5 g/kg OGTT on day 15 (a) and day 30 (b) are shown. Glucose tolerance was significantly improved by liraglutide treatment. Although insulin response was not detected in vehicle treated group, liraglutide improved the response. Insulinogenic index was significantly higher in liraglutide-group than vehicle-group on day 30. White circles and bars represent vehicle-treated group (Veh) (n = 5–6), and black circles and bars represent liraglutide-treated group (Lir) (n = 5–6). *p < 0.05CC BY · PubMed Central
Fig 3 Pancreatic beta cell mass and alpha cell mass. (a) Insulin/glucagon (upper), insulin/Pdx1 (middle), and insulin/FoxO1 (bottom) double immunostaining. Representative images of islets are shown. Scale bars, 100 μm. (b) Beta cell mass. Alloxan treatment markedly decreased beta cell mass. The beta cell mass was two-fold higher in liraglutide-treated mice than that in vehicle-treated mice on day 30. (c) Alpha cell mass. Alpha cell mass did not change by alloxan treatment. Liraglutide did not affect alpha cell mass. White bars represent vehicle-treated group (Veh) (n = 4–9), and black bars represent liraglutide-treated group (Lir) (n = 4–9). *p < 0.05
Fig 3 Pancreatic beta cell mass and alpha cell mass. (a) Insulin/glucagon (upper), insulin/Pdx1 (middle), and insulin/FoxO1 (bottom) double immunostaining. Representative images of islets are shown. Scale bars, 100 μm. (b) Beta cell mass. Alloxan treatment markedly decreased beta cell mass. The beta cell mass was two-fold higher in liraglutide-treated mice than that in vehicle-treated mice on day 30. (c) Alpha cell mass. Alpha cell mass did not change by alloxan treatment. Liraglutide did not affect alpha cell mass. White bars represent vehicle-treated group (Veh) (n = 4–9), and black bars represent liraglutide-treated group (Lir) (n = 4–9). *p < 0.05CC BY · PubMed Central
Fig 4 Proliferation and apoptosis of pancreatic beta cells. (a) Quantification of proliferating beta cells. Photographs are representative images of islets stained for insulin (green) and Ki67 (red). White arrows indicate Ki67- and insulin double-positive cells. Scale bars, 100 μm. The number of Ki67-positive beta cells was significantly increased in liraglutide-group compared to vehicle-group on day 30. (b) Quantification of apoptotic beta cells. Photographs are representative images of islets with insulin and TUNEL staining. White arrows indicate TUNEL- and insulin double-positive cells. Scale bars, 100 μm. The number of TUNEL-positive beta cells was significantly decreased in liraglutide-group compared to vehicle-group. White bars represent vehicle-treated group (Veh) (n = 4–6), and black bars represent liraglutide-treated group (Lir) (n = 4–6). NS, difference not significant. *p < 0.05
Fig 4 Proliferation and apoptosis of pancreatic beta cells. (a) Quantification of proliferating beta cells. Photographs are representative images of islets stained for insulin (green) and Ki67 (red). White arrows indicate Ki67- and insulin double-positive cells. Scale bars, 100 μm. The number of Ki67-positive beta cells was significantly increased in liraglutide-group compared to vehicle-group on day 30. (b) Quantification of apoptotic beta cells. Photographs are representative images of islets with insulin and TUNEL staining. White arrows indicate TUNEL- and insulin double-positive cells. Scale bars, 100 μm. The number of TUNEL-positive beta cells was significantly decreased in liraglutide-group compared to vehicle-group. White bars represent vehicle-treated group (Veh) (n = 4–6), and black bars represent liraglutide-treated group (Lir) (n = 4–6). NS, difference not significant. *p < 0.05CC BY · PubMed Central
Fig 5 Evaluation of beta cell neogenesis. Double immunostaining for insulin (green) and YFP (red) indicates that pancreatic beta cells were specifically labeled by YFP. Scale bars, 100 μm. Quantification of YFP-labeled beta cells shows that the labeling index did not differ before and after liraglutide treatment. Veh, vehicle-treated group; Lir, liraglutide-treated group. Data are means ± SEM of five mice in each group. NS, difference not significant.
Fig 5 Evaluation of beta cell neogenesis. Double immunostaining for insulin (green) and YFP (red) indicates that pancreatic beta cells were specifically labeled by YFP. Scale bars, 100 μm. Quantification of YFP-labeled beta cells shows that the labeling index did not differ before and after liraglutide treatment. Veh, vehicle-treated group; Lir, liraglutide-treated group. Data are means ± SEM of five mice in each group. NS, difference not significant.CC BY · PubMed Central
Fig 6 Oxidative stress assessed by 4-HNE staining. Photographs are representative images of islets stained for insulin (green) and 4-HNE (red). Scale bars, 100 μm. Quantification of 4-HNE-positive cells in islet cells is shown below the photographs. Alloxan treatment induced oxidative stress in pancreatic islets. Liraglutide treatment significantly decreased 4-HNE-positive cells in islet cells. Veh, vehicle-treated group; Lir, liraglutide-treated group. Data are means ± SEM of 4–5 mice in each group. *p < 0.05, **p < 0.01
Fig 6 Oxidative stress assessed by 4-HNE staining. Photographs are representative images of islets stained for insulin (green) and 4-HNE (red). Scale bars, 100 μm. Quantification of 4-HNE-positive cells in islet cells is shown below the photographs. Alloxan treatment induced oxidative stress in pancreatic islets. Liraglutide treatment significantly decreased 4-HNE-positive cells in islet cells. Veh, vehicle-treated group; Lir, liraglutide-treated group. Data are means ± SEM of 4–5 mice in each group. *p < 0.05, **p < 0.01CC BY · PubMed Central
Fig 7 Beta cell function and mass two weeks after withdrawal of liraglutide treatment. (a) Casual blood glucose levels. Non-fasting blood glucose levels tended to be lower in liraglutide-treated group (n = 6) than in vehicle-treated group (n = 4). (b) Blood glucose levels (left) and serum insulin levels (right) during 1.5 g/kg OGTT. Liraglutide-treated group (n = 4) showed improved glucose tolerance as well as insulin response compared with vehicle-treated group (n = 3). (c) Beta cell mass. Beta cell mass was significantly higher in liraglutide-treated mice (n = 5) than in vehicle-treated mice (n = 3). (d) Insulin/glucagon (upper), insulin/Pdx1 (middle), and insulin/FoxO1 (bottom) double immunostaining. Representative images of islets are shown. Veh, vehicle-treated group; Lir, liraglutide-treated group. *p < 0.05.
Fig 7 Beta cell function and mass two weeks after withdrawal of liraglutide treatment. (a) Casual blood glucose levels. Non-fasting blood glucose levels tended to be lower in liraglutide-treated group (n = 6) than in vehicle-treated group (n = 4). (b) Blood glucose levels (left) and serum insulin levels (right) during 1.5 g/kg OGTT. Liraglutide-treated group (n = 4) showed improved glucose tolerance as well as insulin response compared with vehicle-treated group (n = 3). (c) Beta cell mass. Beta cell mass was significantly higher in liraglutide-treated mice (n = 5) than in vehicle-treated mice (n = 3). (d) Insulin/glucagon (upper), insulin/Pdx1 (middle), and insulin/FoxO1 (bottom) double immunostaining. Representative images of islets are shown. Veh, vehicle-treated group; Lir, liraglutide-treated group. *p < 0.05.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

The citation lists are queued

They are fetched later and appear here then.

References 44 · Cited by 70

Research works printed but not linked: 1

  1. K Minami, 2011, Self-replication is not the only mechanism of maintenance of pancreatic beta cell mass after birth, Diabetologia, 54, S26

Metadata

Authors
Tamura, K., Minami, K., Kudo, M., Iemoto, K., Takahashi, H., & Seino, S.
Affiliations
Kobe University (JP)
Corresponding author
  • Minami, Kohtaro
  • Seino, Susumu
Venue
PLOS ONE
Published
2015-05-04
Volume
10
Issue
5
Pages
e0126003
ISSN
1932-6203 (ISSN-L)
OpenAlex
W2161155577
Cited by
70
References
44
Citations by year
2026: 5 · 2025: 6 · 2024: 6 · 2023: 4 · 2022: 4 · 2021: 10 · 2020: 10 · 2019: 3 · 2018: 10 · 2017: 10 · 2015: 2
FWCI
7.38
Type
journal article
Language
en
Open access
Locations
  • PLoS ONE (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Kobe University Repository Kernel (Kobe University) (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Figshare (submittedVersion, cc-by)
Funders
  • Novo Nordisk
  • Novo Nordisk Pharma
  • Japan Society for the Promotion of Science (24229007, 25461351)
  • Japan Science and Technology Agency (CREST)
  • Core Research for Evolutional Science and Technology
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Diabetes and associated disorders
Keywords
liraglutide, GLP-1 receptor agonists, beta-cell mass, beta-cell proliferation, beta-cell apoptosis, alloxan-induced diabetes, glucose tolerance, insulin secretion, oxidative stress, neogenesis, drug withdrawal
MeSH terms
Liraglutide, Alloxan, Animals, Blood Glucose, Diabetes Mellitus, Experimental, Energy Metabolism, Glucose Tolerance Test, Hyperglycemia, Hypoglycemic Agents, Insulin, Mice, Transgenic, Apoptosis, Oxidative Stress, Cell Size, Cell Proliferation, Insulin-Secreting Cells, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Liraglutide Improves Pancreatic Beta Cell Mass and Function in Alloxan-Induced Diabetic Mice. https://app.cochat.ai/papers/10.1371/journal.pone.0126003
The paper
Tamura, K., Minami, K., Kudo, M., Iemoto, K., Takahashi, H., & Seino, S. (2015). Liraglutide Improves Pancreatic Beta Cell Mass and Function in Alloxan-Induced Diabetic Mice. PLOS ONE. https://doi.org/10.1371/journal.pone.0126003

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.